Please wait a minute...
Protein & Cell

ISSN 1674-800X

ISSN 1674-8018(Online)

CN 11-5886/Q

Postal Subscription Code 80-984

2018 Impact Factor: 7.575

Protein Cell    2021, Vol. 12 Issue (7) : 557-577    https://doi.org/10.1007/s13238-020-00754-2
RESEARCH ARTICLE
Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network
Yu-Kun Xia1,2, Yi-Rong Zeng1,2, Meng-Li Zhang1,2,3, Peng Liu1,2, Fang Liu4, Hao Zhang5,6, Chen-Xi He1, Yi-Ping Sun1,2, Jin-Ye Zhang1,2, Cheng Zhang1,2, Lei Song7,8, Chen Ding9, Yu-Jie Tang4, Zhen Yang1, Chen Yang5,6, Pu Wang1,2, Kun-Liang Guan10, Yue Xiong11, Dan Ye1,2,12()
1. Huashan Hospital, Fudan University, and Molecular and Cell Biology Lab, Institutes of Biomedical Sciences, and the Shanghai Key Laboratory of Medical Epigenetics, and the Key Laboratory of Metabolism and Molecular, Ministry of Education, Shanghai 200032, China
2. The International Co-Laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Shanghai 200032, China
3. Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200032, China
4. Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
5. Key Laboratory of Synthetic Biology, Institute of Plant Physiology and Ecology, Shanghai 200032, China
6. Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200032, China
7. State Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, Beijing 102206, China
8. National Center for Protein Sciences (The PHOENIX Center, Beijing), Beijing 102206, China
9. State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China
10. Department of Pharmacology and Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
11. Lineberger Comprehensive Cancer Center, Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC, USA
12. Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200032, China
 Download: PDF(3187 KB)  
 Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract

Additional sex combs-like 1 (ASXL1) interacts with BRCA1-associated protein 1 (BAP1) deubiquitinase to oppose the polycomb repressive complex 1 (PRC1)-mediated histone H2A ubiquitylation. Germline BAP1 mutations are found in a spectrum of human malignancies, while ASXL1 mutations recurrently occur in myeloid neoplasm and are associated with poor prognosis. Nearly all ASXL1 mutations are heterozygous frameshift or nonsense mutations in the middle or to a less extent the C-terminal region, resulting in the production of C-terminally truncated mutant ASXL1 proteins. How ASXL1 regulates specific target genes and how the C-terminal truncation of ASXL1 promotes leukemogenesis are unclear. Here, we report that ASXL1 interacts with forkhead transcription factors FOXK1 and FOXK2 to regulate a subset of FOXK1/K2 target genes. We show that the C-terminally truncated mutant ASXL1 proteins are expressed at much higher levels than the wild-type protein in ASXL1 heterozygous leukemia cells, and lose the ability to interact with FOXK1/K2. Specific deletion of the mutant allele eliminates the expression of C-terminally truncated ASXL1 and increases the association of wild-type ASXL1 with BAP1, thereby restoring the expression of BAP1-ASXL1-FOXK1/K2 target genes, particularly those involved in glucose metabolism, oxygen sensing, and JAK-STAT3 signaling pathways. In addition to FOXK1/K2, we also identify other DNA-binding transcription regulators including transcription factors (TFs) which interact with wild-type ASXL1, but not C-terminally truncated mutant. Our results suggest that ASXL1 mutations result in neomorphic alleles that contribute to leukemogenesis at least in part through dominantly inhibiting the wild-type ASXL1 from interacting with BAP1 and thereby impairing the function of ASXL1-BAP1-TF in regulating target genes and leukemia cell growth.

Keywords ASXL1      BAP1      FOXK1/K2      leukemia      epigenetics     
Corresponding Author(s): Dan Ye   
Online First Date: 14 September 2020    Issue Date: 04 August 2021
 Cite this article:   
Yu-Kun Xia,Yi-Rong Zeng,Meng-Li Zhang, et al. Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network[J]. Protein Cell, 2021, 12(7): 557-577.
 URL:  
https://academic.hep.com.cn/pac/EN/10.1007/s13238-020-00754-2
https://academic.hep.com.cn/pac/EN/Y2021/V12/I7/557
1 O Abdel-Wahab, J Gao, M Adli, A Dey, T Trimarchi, YR Chung, C Kuscu, T Hricik, D Ndiaye-Lobry, LM Lafaveet al. (2013) Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med 210:2641–2659
https://doi.org/10.1084/jem.20131141
2 S Asada, S Goyama, D Inoue, S Shikata, R Takeda, T Fukushima, T Yonezawa, T Fujino, Y Hayashi, KC Kawabataet al. (2018) Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis. Nat Commun 9:2733
https://doi.org/10.1038/s41467-018-05085-9
3 A Balasubramani, A Larjo, JA Bassein, X Chang, RB Hastie, SM Togher, H Lahdesmaki, A Rao (2015) Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex. Nat Commun 6:7307
https://doi.org/10.1038/ncomms8307
4 A Campagne, MK Lee, D Zielinski, A Michaud, S Le Corre, F Dingli, H Chen, LZ Shahidian, I Vassilev, N Servantet al. (2019) BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation. Nat Commun 10:348
https://doi.org/10.1038/s41467-018-08255-x
5 C Dell'Aversana, C Giorgio, L D'Amato, G Lania, F Matarese, S Saeed, A Di Costanzo , V Belsito Petrizzi, C Ingenito, JHA Martenset al. (2017) miR-194-5p/BCLAF1 deregulation in AML tumorigenesis. Leukemia 31:2315–2325
https://doi.org/10.1038/leu.2017.64
6 A Dey, D Seshasayee, R Noubade, DM French, J Liu, MS Chaurushiya, DS Kirkpatrick, VC Pham, JR Lill, CE Bakalarskiet al. (2012) Loss of the tumor suppressor BAP1 causes myeloid transformation. Science 337:1541–1546
https://doi.org/10.1126/science.1221711
7 SA Duncan, DR Baganizi, R Sahu, SR Singh, VA Dennis (2017) SOCS proteins as regulators of inflammatory responses induced by bacterial infections: a review. Front Microbiol 8:2431
https://doi.org/10.3389/fmicb.2017.02431
8 CL Fisher, N Pineault, C Brookes, CD Helgason, H Ohta, C Bodner, JL Hess, RK Humphries, HW Brock (2010) Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 115:38–46
https://doi.org/10.1182/blood-2009-07-230698
9 N Gao (2005) Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development 132:3431–3443
https://doi.org/10.1242/dev.01917
10 V Gelsi-Boyer, M Brecqueville, R Devillier, A Murati, MJ Mozziconacci, D Birnbaum (2012) Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol 5:12
https://doi.org/10.1186/1756-8722-5-12
11 L Gossage, T Eisen, ER Maher (2015) VHL, the story of a tumour suppressor gene. Nat Rev Cancer 15:55–64
https://doi.org/10.1038/nrc3844
12 EM Heath, SM Chan, MD Minden, T Murphy, LI Shlush, AD Schimmer (2017) Biological and clinical consequences of NPM1 mutations in AML. Leukemia 31:798–807
https://doi.org/10.1038/leu.2017.30
13 YC Hsu, YC Chiu, CC Lin, YY Kuo, HA Hou, YS Tzeng, CJ Kao, PH Chuang, MH Tseng, TH Hsiaoet al. (2017) The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model. J Hematol Oncol 10:139
https://doi.org/10.1186/s13045-017-0508-x
14 D Inoue, J Kitaura, K Togami, K Nishimura, Y Enomoto, T Uchida, Y Kagiyama, KC Kawabata, F Nakahara, K Izawaet al. (2013) Myelodysplastic syndromes are induced by histone methylationaltering ASXL1 mutations. J Clin Investig 123:4627–4640
https://doi.org/10.1172/JCI70739
15 D Inoue, M Matsumoto, R Nagase, M Saika, T Fujino, KI Nakayama, T Kitamura (2016) Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels. Exp Hematol 44:172–176.e171
https://doi.org/10.1016/j.exphem.2015.11.011
16 Z Ji, H Mohammed, A Webber, J Ridsdale, N Han, JS Carroll, AD Sharrocks (2014) The forkhead transcription factor FOXK2 acts as a chromatin targeting factor for the BAP1-containing histone deubiquitinase complex. Nucleic Acids Res 42:6232–6242
https://doi.org/10.1093/nar/gku274
17 M Jiang, WW Zhang, P Liu, W Yu, T Liu, J Yu (2017) Dysregulation of SOCS-mediated negative feedback of cytokine signaling in carcinogenesis and its significance in cancer treatment. Front Immunol 8:70
https://doi.org/10.3389/fimmu.2017.00070
18 F Lan, RE Collins, R De Cegli, R Alpatov, JR Horton, X Shi, O Gozani, X Cheng, Y Shi (2007) Recognition of unmethylated histone H3 lysine 4 links BHC80 to LSD1-mediated gene repression. Nature 448:718–722
https://doi.org/10.1038/nature06034
19 K Labno-Kirszniok, T Nieszporek, A Wiecek, G Helbig, J Lubinski (2013) Acute myeloid leukemia in a 38-year-old hemodialyzed patient with von Hippel-Lindau disease. Hered Cancer Clin Pract 11:11
https://doi.org/10.1186/1897-4287-11-11
20 X Li, Y Xue, X Liu, J Zheng, S Shen, C Yang, J Chen, Z Li, L Liu, J Maet al. (2019) ZRANB2/SNHG20/FOXK1 Axis regulates Vasculogenic mimicry formation in glioma. J Exp Clin Cancer Res 38(1):68
https://doi.org/10.1186/s13046-018-1003-0
21 YJ Machida, Y Machida, AA Vashisht, JA Wohlschlegel, A Dutta (2009) The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J Biol Chem 284:34179–34188
https://doi.org/10.1074/jbc.M109.046755
22 JB Micol, O Abdel-Wahab (2016) The role of additional sex combslike proteins in cancer. Cold Spring Harb Perspect Med 6(10):a026526
https://doi.org/10.1101/cshperspect.a026526
23 IC Moura, H Zhang, G Song, G Song, R Li, M Gao, L Ye, C Zhang (2018) Identification of DNA methylation prognostic signature of acute myelocytic leukemia. PLoS ONE.
https://doi.org/10.1371/journal.pone.0199689
24 R Nagase, D Inoue, A Pastore, T Fujino, HA Hou, N Yamasaki, S Goyama, M Saika, A Kanai, Y Seraet al. (2018) Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation. J Exp Med 215:1729–1747
https://doi.org/10.1084/jem.20171151
25 K Nishizawa, H Nishiyama, Y Matsui, T Kobayashi, R Saito, H Kotani, H Masutani, S Oishi, Y Toda, N Fujiiet al. (2011) Thioredoxininteracting protein suppresses bladder carcinogenesis. Carcinogenesis 32:1459–1466
https://doi.org/10.1093/carcin/bgr137
26 DD Sahtoe, WJ van Dijk, R Ekkebus, H Ovaa, TK Sixma (2016) BAP1/ASXL1 recruitment and activation for H2A deubiquitination. Nat Commun 7:10292
https://doi.org/10.1038/ncomms10292
27 L Sanchez-Pulido, L Kong, CP Ponting (2012) A common ancestry for BAP1 and Uch37 regulators. Bioinformatics (Oxf Engl) 28:1953–1956
https://doi.org/10.1093/bioinformatics/bts319
28 JC Scheuermann, AG de Ayala Alonso, K Oktaba, N Ly-Hartig, RK McGinty, S Fraterman, M Wilm, TW Muir, J Muller (2010) Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 465:243–247
https://doi.org/10.1038/nature08966
29 S Schnittger, C Eder, S Jeromin, T Alpermann, A Fasan, V Grossmann, A Kohlmann, T Illig, N Klopp, HE Wichmannet al. (2013) ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia 27:82–91
https://doi.org/10.1038/leu.2012.262
30 DA Sinclair, TA Milne, JW Hodgson, J Shellard, CA Salinas, M Kyba, F Randazzo, HW Brock (1998) The Additional sex combs gene of Drosophila encodes a chromatin protein that binds to shared and unique Polycomb group sites on polytene chromosomes. Development 125:1207–1216
31 P Sportoletti, L Celani, E Varasano, R Rossi, D Sorcini, C Rompietti, F Strozzini, B Del Papa, V Guarente, G Spinozziet al. (2019) GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations. Leukemia 33:1827–1832
https://doi.org/10.1038/s41375-019-0399-7
32 V Sukonina, H Ma, W Zhang, S Bartesaghi, S Subhash, M Heglind, H Foyn, MJ Betz, D Nilsson, ME Lidellet al. (2019) FOXK1 and FOXK2 regulate aerobic glycolysis. Nature 566:279–283
https://doi.org/10.1038/s41586-019-0900-5
33 T Sun, H Wang, Q Li, Z Qian, C Shen (2016) Forkhead box protein k1 recruits TET1 to act as a tumor suppressor and is associated with MRI detection. Jpn J Clin Oncol 46:209–221
https://doi.org/10.1093/jjco/hyv185
34 SJ Thomas, JA Snowden, MP Zeidler, SJ Danson (2015) The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer 113:365–371
https://doi.org/10.1038/bjc.2015.233
35 C Trapnell, L Pachter, SL Salzberg (2009) TopHat: discovering splice junctions with RNA-Seq. Bioinform 25:1105–1111
https://doi.org/10.1093/bioinformatics/btp120
36 RG Verhaak, CS Goudswaard, W van Putten, MA Bijl, MA Sanders, W Hugens, AG Uitterlinden, CA Erpelinck, R Delwel, B Lowenberget al. (2005) Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106:3747–3754
https://doi.org/10.1182/blood-2005-05-2168
37 AN Waldhart, H Dykstra, AS Peck, EA Boguslawski, ZB Madaj, J Wen, K Veldkamp, M Hollowell, B Zheng, LC Cantleyet al. (2017) Phosphorylation of TXNIP by AKT mediates acute influx of glucose in response to insulin. Cell Rep 19:2005–2013
https://doi.org/10.1016/j.celrep.2017.05.041
38 AE White, JW Harper (2012) Cancer. Emerging anatomy of the BAP1 tumor suppressor system. Science 337:1463–1464
https://doi.org/10.1126/science.1228463
39 EA Williamson, I Wolf, J O’Kelly, S Bose, S Tanosaki, HP Koeffler (2005) BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27Kip1. Oncogene 25:1391–1399
https://doi.org/10.1038/sj.onc.1209170
40 H Yang, S Kurtenbach, Y Guo, I Lohse, MA Durante, J Li, Z Li, H Al-Ali, L Li, Z Chenet al. (2018) Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies. Blood 131:328–341
https://doi.org/10.1182/blood-2017-06-789669
41 H Yu, N Mashtalir, S Daou, I Hammond-Martel, J Ross, G Sui, GW Hart, FJ III Rauscher, E Drobetsky, E Milotet al. (2010) The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Mol Cell Biol 30:5071–5085
https://doi.org/10.1128/MCB.00396-10
[1] PAC-0557-20234-YD_suppl_1 Download
[2] PAC-0557-20234-YD_suppl_2 Download
[3] PAC-0557-20234-YD_suppl_3 Download
[4] PAC-0557-20234-YD_suppl_4 Download
[5] PAC-0557-20234-YD_suppl_5 Download
[6] PAC-0557-20234-YD_suppl_6 Download
[1] Yuliang Feng, Xingguo Liu, Siim Pauklin. 3D chromatin architecture and epigenetic regulation in cancer stem cells[J]. Protein Cell, 2021, 12(6): 440-454.
[2] Mona Teng, Stanley Zhou, Changmeng Cai, Mathieu Lupien, Housheng Hansen He. Pioneer of prostate cancer: past, present and the future of FOXA1[J]. Protein Cell, 2021, 12(1): 29-38.
[3] Qingfei Zheng, Igor Maksimovic, Akhil Upad, Yael David. Non-enzymatic covalent modifications: a new link between metabolism and epigenetics[J]. Protein Cell, 2020, 11(6): 401-416.
[4] Lin-Yong Zhao, Jinghui Song, Yibin Liu, Chun-Xiao Song, Chengqi Yi. Mapping the epigenetic modifications of DNA and RNA[J]. Protein Cell, 2020, 11(11): 792-808.
[5] Lili Yu, Kai-yuan Ji, Jian Zhang, Yanxia Xu, Yue Ying, Taoyi Mai, Shuxiang Xu, Qian-bing Zhang, Kai-tai Yao, Yang Xu. Core pluripotency factors promote glycolysis of human embryonic stem cells by activating GLUT1 enhancer[J]. Protein Cell, 2019, 10(9): 668-680.
[6] Xiangxian Zhang, Li Liu, Xia Yuan, Yuquan Wei, Xiawei Wei. JMJD3 in the regulation of human diseases[J]. Protein Cell, 2019, 10(12): 864-882.
[7] Yan Jiang,Yanping Zhu,Zhi-Jie Liu,Songying Ouyang. The emerging roles of the DDX41 protein in immunity and diseases[J]. Protein Cell, 2017, 8(2): 83-89.
[8] Donglu Wu, Yong Cai, Jingji Jin. Potential coordination role between O-GlcNAcylation and epigenetics[J]. Protein Cell, 2017, 8(10): 713-723.
[9] Haley Vaseghi, Jiandong Liu, Li Qian. Molecular barriers to direct cardiac reprogramming[J]. Protein Cell, 2017, 8(10): 724-734.
[10] Hong Zhou,Rongzhen Xu. Leukemia stem cells: the root of chronic myeloid leukemia[J]. Protein Cell, 2015, 6(6): 403-412.
[11] David M. Roy,Logan A. Walsh,Timothy A. Chan. Driver mutations of cancer epigenomes[J]. Protein Cell, 2014, 5(4): 265-296.
[12] Yeqing Angela Yang, Jindan Yu. EZH2, an epigenetic driver of prostate cancer[J]. Prot Cell, 2013, 4(5): 331-341.
[13] Haojian Zhang, Shaoguang Li. Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells[J]. Prot Cell, 2013, 4(3): 186-196.
[14] Grace L. Peloquin, Yi-Bin Chen, Amir T. Fathi. The evolving landscape in the therapy of acute myeloid leukemia[J]. Prot Cell, 2013, 4(10): 735-746.
[15] Hua Cheng, Tong Ren, Shao-cong Sun. New insight into the oncogenic mechanism of the retroviral oncoprotein Tax[J]. Prot Cell, 2012, 3(8): 581-589.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed